Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04156633
Other study ID # 2019-01860; qu19Egli2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 17, 2019
Est. completion date July 31, 2022

Study information

Verified date May 2024
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this before-after study, different new methods for bacterial species identification from positive blood cultures will be compared towards historic controls. All samples are analyzed within the routine workflow for bacterial species identification and antibiotic resistance profiling. Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls) will be compared to patients from 2018 and 2019 with a new identification method (cases). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or Matrix-assisted Laser-Desorption/Ionization Time-of-Flight (MALDI-TOF MS). The new identification of positive blood cultures methods include (i) either the newly introduced Biofire FilmArray© Blood Culture Identification (BCID) panel or (ii) in a subset of patients whole genome sequencing (WGS) approaches.


Recruitment information / eligibility

Status Completed
Enrollment 800
Est. completion date July 31, 2022
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients with positive blood cultures hospitalized between August 2016 and October 2019 - documented refusal of the general consent Exclusion Criteria: - outpatients - patients hospitalized in other hospitals - patients with known bacteremia diagnosed in another hospital

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
conventional identification method: biochemical profiling or MALDI-TOF MS
Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
new identification method: Biofire FilmArray© BCID panel
The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
new identification method: metagenomic WGS
shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)

Locations

Country Name City State
Switzerland Division of Clinical Bacteriology & Mycology, University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Agnetti J, Buchler AC, Osthoff M, Helfenstein F, Weisser M, Siegemund M, Bassetti S, Bingisser R, Schaefer DJ, Clauss M, Hinic V, Tschudin-Sutter S, Battig V, Khanna N, Egli A. Identification of microorganisms by a rapid PCR panel from positive blood cult — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to optimal antibiotic treatment in hours from positive blood cultures (hours) Time from blood draw for blood culture testing to start of optimal antibiotic treatment (hours) 24 hours from collection of blood cultures
Secondary Time to effective antibiotic treatment in hours from positive blood cultures (hours) Time from blood draw for blood culture testing to start of effective antibiotic treatment (hours) 24 hours from collection of blood cultures
Secondary all-cause in hospital mortality (number) all-cause in hospital mortality (number) from admission to hospital until release from hospital (approximately 30 days)
Secondary duration on ICU in days duration on ICU in days from admission to ICU until release from ICU (approximately 20 days)
Secondary time to Gram staining and resistance profile from positive blood cultures (hours) time to Gram staining and resistance profile from positive blood cultures (hours) 24 hours from collection of blood cultures
See also
  Status Clinical Trial Phase
Completed NCT03869437 - RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI Phase 2
Terminated NCT02176122 - RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp. Phase 4
Recruiting NCT06418048 - INfectious DIsease REgistry BIObank
Completed NCT02437045 - Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response Phase 4
Completed NCT01576003 - Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants N/A